SCHEDULE 13G/A: BlackRock Discloses 10.2% Beneficial Ownership in Exelixis, Inc.
Beneficial Ownership Report
BlackRock, Inc. has filed an amended Schedule 13G, reporting a 10.2% beneficial ownership stake in Exelixis, Inc. common stock as of March 31, 2025.
Summary
- BlackRock, Inc. reported beneficial ownership of 28,499,470 shares of Exelixis, Inc. common stock.
- This ownership represents 10.2% of the total outstanding common stock of Exelixis, Inc.
- BlackRock holds sole voting power over 27,706,393 shares.
- BlackRock holds sole dispositive power over 28,499,470 shares.
- No shared voting or dispositive power was reported by BlackRock.
- The filing is an Amendment No. 18 to the Schedule 13G, indicating an update to a previously reported stake.
- BlackRock certifies that the securities were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Exelixis, Inc.
- BlackRock Fund Advisors, a subsidiary of BlackRock, Inc., is specifically noted as beneficially owning 5% or greater of the outstanding shares.
Sentiment
Score: 5
Explanation: The document is a factual disclosure of beneficial ownership and does not contain positive or negative performance indicators or forward-looking statements about the issuer. The sentiment is neutral as it simply reports a significant, passive institutional stake.
Future Outlook
NA
Industry Context
This Schedule 13G filing indicates a significant institutional investment by BlackRock, one of the world's largest asset managers, in Exelixis, Inc., a biopharmaceutical company. Such a substantial stake (10.2%) by a major institutional investor can signal confidence in the company's long-term prospects within the biotechnology and pharmaceutical sector, although the filing itself is a passive disclosure and does not imply active management involvement or strategic intent beyond ordinary course of business.
Stakeholder Impact
- For shareholders, the disclosure of BlackRock's 10.2% beneficial ownership stake in Exelixis, Inc. by a major institutional investor may be viewed as a positive signal of confidence in the company's value and future prospects.
Key Dates
| Date | Description |
|---|---|
| 2023-04-30 | Date of previous Power of Attorney, which was expressly revoked. |
| 2025-01-21 | Effective date of the new Power of Attorney for BlackRock, Inc. |
| 2025-03-31 | Date of event which requires filing of this statement (reporting date for ownership). |
| 2025-04-28 | Date of filing and signature by BlackRock, Inc. |
Keywords
Exelixis, BlackRock, Schedule 13G, beneficial ownership, common stock, institutional investor, SEC filing, ownership disclosure, pharmaceuticals, biotechnology
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.